Anthem Biosciences IPO Allotment Status – Check Your Application

The allotment of Anthem Biosciences Ltd. shares is scheduled for Thursday, July 17, 2025. With intense investor participation across the board—from retail to institutional—today marks the day when many await confirmation: did they secure shares or not?

How to Check Your Allotment 

Investors can verify their allotment status on three platforms:

1. KFin Technologies (Registrar)

   • Visit the KFin portal → select Anthem Biosciences IPO → enter PAN, application number, DP‑Client‑ID, or bank account → click "Submit." 

2. NSE Website

   • Go to "Equity & SME IPO Bid Details" → select Anthem Biosciences → input PAN and application number → click "Submit." 

3. BSE Website

   • Navigate to "Application Status Check" under Investor Services → choose Equity and the company → enter PAN or application number → complete the captcha → click "Search." 

Allotment Timeline at a Glance 

• Bids closed on July 16, and allotment is expected today, July 17.

• Successful applicants receive shares in their Demat a/c; others get refunds by July 18.

• Listing earmarked for July 21 on NSE and BSE.

Multiple Route Check: Your Allotment, Step-by-Step

• Registrar (KFin)

• NSE Platform

• BSE Platform

Steps are straightforward and mirrored across platforms—select company, input credentials, view status.

Subscription Details & Market Sentiment

This IPO witnessed astounding demand, with total subscriptions soaring to approximately 63.86×. Breakdown by segment:

• Qualified Institutional Buyers (QIBs): ~182.65×

• Non-Institutional Investors (NIIs): ~42.35×

• Retail Investors (RIIs): ~5.64×

• Employee Quota: ~6.6× (up to ~7×) 

Such oversubscription levels reflect overwhelming investor confidence and institutional interest.

Grey Market Premium (GMP)

The GMP, reflecting informal demand ahead of listing, is strong:

• ₹144 per share (~25.26%) above issue price → projected listing price ~₹714 

Some sources even show GMP touching ₹151 (26–27% potential)—highlighting bullish sentiment. However, note that GMP is unofficial and may fluctuate.

About Anthem Biosciences

• Founded in 2006, headquartered in Bengaluru

• Operates as a CRDMO (Contract Research, Development & Manufacturing Org.)

• Offers services across drug discovery, development, and scale-up

• Focus areas include fermentation-based APIs, biosimilars, peptides, enzymes, and nutritional actives

• Serves 44 countries, including pharma giants and startups in the US, EU, and Japan 

• FY24–25 revenue: ~₹1,840–₹1,930 crore; Net profit: ~₹450 crore; EBITDA margin ~36–37% 

Why This IPO Attracted Attention 

1. Uniqueness in CRDMO – ⁠Integrated small & large molecule capabilities, including NCE/NBE, ADC, RNAi, flow chemistry.

2. Robust Global Pipeline – Over 8,000 completed projects, 675+ clients, 242 active projects. 

3. Strong Financials – Record revenue growth (~30%), high earnings quality.

4. Positive GMP Signals – Market pricing suggests 25–27% listing gains.

5. Seasoned Lead Manager – JM Financial & KFin Technologies providing strong infrastructure. 

What Investors Can Expect Next

• Allotment today (July 17)

• Shares credited/refunds by July 18

• Listing on July 21 — likely to open with premium, per GMP cues

Tips:

• Check multiple platforms (Registrar, NSE, BSE) for status

• Monitor grey market movements, but treat cautiously

• Plan exit or hold strategy based on listing-day price action and long-term view

• Watch peer CRDMOs to assess relative valuations post-listing

Summary

• Allotment Date: July 17, 2025

• Subscription: ~63.86× overall; QIB 182×, NII 42×, Retail 5.6×

• GMP: ₹144–151, indicating ~25–27% expected listing upswing

• Listing: July 21, 2025

• P/F: Solid business model, deep R&D pipeline, global reach, strong financial health

Final Thoughts

If you applied, check your status now via KFin, NSE, or BSE. The robust subscription and GMP signal promise for a successful debut. But always strategize for the listing day and beyond—whether you aim for a listing pop or believe in the company’s long-term growth.

Best of luck—here’s hoping your Demat account lights up today! ????